Analysis of:
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer (jco.ascopubs.org)
Lapatinib, an oral HER-2 inhibitor, is effective in monotherapy in HER-2+ metastatic breast cancer.
Analysis of:
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 (content.nejm.org)
"In summary, THEY showed that the infusion of a clonal population of CD4+ T cells with specificity for a single tumor-associated antigen caused complete regression of a tumor. During regression of the tumor, this clone appears to have induced the patient's own T cells to respond to other antigens of...
Analysis of:
Researchers Fail to Reveal Full Drug Pay (www.nytimes.com)
This article reveals the things we all know to be inherent parts of human nature and the human experience: 1. People are greedy and will take money or goods when offered, unless the risk of taking exceeds the benefit of the money or goods received. 2. In large universities or small...
Analysis of:
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders (bloodjournal.hematologylibrary.org)
Very preliminary but this agent may offer a targeted, more "natural" approach to the MPD's- Polycythemia Vera, Myelofibrosis and Primary thrombocytosis.
Analysis of:
Tight Rein on Blood Sugar Has No Heart Benefit (www.nytimes.com)
Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.
Analysis of:
Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer (www.pipelinereview.com)
This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)
Analysis of:
Positive data on Antisoma’s ASA404 presented at ASCO (www.pipelinereview.com)
That appears to be a well contructed phase III trial adds ASA404 or a placebo to Taxol/Carboplatin. Nothing exotic, endpoints are overall survival (OS) as well as OS in Squams and non Squams.
Analysis of:
Genetic Research May Help Pick Patients' Best Cancer Drugs (online.wsj.com)
Genetic profiling will tell us who should or should not receive particular anti neoplastic agents. This is "personalized" therapy that has been predicted x years.
Analysis of:
Boehringer Ingelheim gets first approval within EU for Actilyse(R) 2mg to treat catheter dysfunction caused by thrombotic occlusion (www.pipelinereview.com)
This is just a "me too" product purchased from Genetech - was call Cathflo when sold by Genentech. We draw up the same chemical called alteplase (TPA) in 2 mg increments in order not to waste same when we use the drug for emergent treatment of strokes, then freeze the...
Analysis of:
Drug Brings ImClone in From Cold (online.wsj.com)
Well we know that the lung cancer trial http://online.wsj.com/article/SB121227163771635641.html?mod=2_1566_topbox was a bust so far. What other "good news" do we await